PPIDT00388
Drug Information
| Name | Galcanezumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG |
| DrugBank_ID | DB14042 |
| Type | biotech |
| Indication | Galcanezumab is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.[L42060] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
120 MG
|
| Injection, solution | Subcutaneous |
100 mg/1mL
|
| Injection, solution | Subcutaneous |
120 mg
|
| Injection, solution | Subcutaneous |
120 mg/1mL
|
| Solution | Subcutaneous |
100 mg / mL
|
| Solution | Subcutaneous |
120 mg / mL
|
| Solution | Subcutaneous |
120 mg
|
| Solution | Subcutaneous |
12000000 mg
|
| Injection, solution | — |
100 mg/ml
|
| Injection, solution | — |
120 mg/ml
|
| Injection, solution | Subcutaneous |
120 mg/ml
|
| Injection, solution | Subcutaneous |
100 mg/ml
|